Влияние Инчэньхао Танга на холестатические повреждения печени и механизмы регуляции

  • role: First author第一作者
  • Affiliation:

    Henan University of Chinese Medicine,Zhengzhou 450046,China

    Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao,Zhengzhou 450046,China

  • Email:704331163@qq.com
  • Introduction:王琳琳,在读硕士,从事中医药防治消化系统疾病研究,E-mail:704331163@qq.com
WANG Linlin12,  
  • Affiliation:

    Henan University of Chinese Medicine,Zhengzhou 450046,China

    Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao,Zhengzhou 450046,China

ZHU Zhengwang12,  
  • Affiliation:

    Henan University of Chinese Medicine,Zhengzhou 450046,China

    Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao,Zhengzhou 450046,China

ZHAO Jinghan12,  
  • Affiliation:

    Henan University of Chinese Medicine,Zhengzhou 450046,China

MA Ruixue1,  
  • Affiliation:

    Shanghai Sixth People 's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200233,China

WANG Bing3,  
  • role: Corresponding author通信作者
  • Affiliation:

    Henan University of Chinese Medicine,Zhengzhou 450046,China

    Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao,Zhengzhou 450046,China

  • Email:zhupingsheng@126.com
  • Introduction:朱平生,博士,教授,从事中医药防治肝胆系统疾病研究,E-mail:zhupingsheng@126.com
ZHU Pingsheng12*,  
  • Affiliation:

    Henan University of Chinese Medicine,Zhengzhou 450046,China

    Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao,Zhengzhou 450046,China

MIAO Mingsan12

реферат

Холестатическое повреждение печени относится к заболеваниям гепатобилиарной системы, вызванным различными причинами, которые приводят к нарушению образования, секреции и выведения желчи, что вызывает холестаз и последующее повреждение печени, метаболические нарушения и дисфункцию. Это состояние может прогрессировать до печеночного фиброза, цирроза, печеночной недостаточности и даже смерти. В настоящее время препарат выбора в клинической практике — урсодезоксихолевая кислота, однако есть проблемы с нежелательными реакциями и непереносимостью у части пациентов. Сбор трав Инчэньхао (Yinchenhao Tang) является 대표енным рецептом традиционной китайской медицины для лечения желтухи янской формы, обладающим эффектами «очищения жары, устранения влажности и снижения желтухи». Длительное клиническое применение показало хорошую эффективность, а современные фармакологические исследования выявили его гепатопротекторные свойства, включая противовоспалительное, антиоксидантное действие, регулирование баланса желчных кислот и подавление апоптоза гепатоцитов. Анализируя последние клинические и экспериментальные исследования применения Инчэньхао Танга при холестатических повреждениях печени, обнаружено, что он воздействует на патогенез заболевания путем регуляции обмена и выведения желчных кислот, снижения воспалительной реакции, ингибирования окислительного стресса, ослабления эндоплазматического стрессового ответа (ERS), подавления апоптоза гепатоцитов и защиты кишечного слизистого барьера. Систематическое изложение молекулярных механизмов регуляции Инчэньхао Танга при холестатических повреждениях печени предоставит основу для клинического применения и дальнейших исследований этого рецепта.

ключеви́че слова́

Инчэньхао Тан; холестаз; обмен и выведение желчных кислот; воспалительная реакция; апоптоз

References

  1. 1.
    YANG Y,ZHANG G Z,LIU T,et al.Characteristics and regulatory mechanisms of cholestatic liver injury caused by Chinese herbal medicines[J].Chin J Exp Tradit Med Form,2024,30(23):64-71.
  2. 2.
    SONG S L,LI X,GENG C,et al.Uncovering key molecules and immune landscape in cholestatic liver injury:Implications for pathogenesis and drug therapy[J].Front Pharmacol,2023,14:1171512.
  3. 3.
    ZHANG Y D,LIU Y,HUO W,et al.The role of miRNA and long noncoding RNA in cholestatic liver diseases[J].Am J Pathol,2024,194(6):879-893.
  4. 4.
    MÉNDEZ-SÁNCHEZ N,CORONEL-CASTILLO C E,ORDOÑEZ-VÁZQUEZ A L.Current therapies for cholestatic diseases[J].Biomedicines,2023,11(6):1713.
  5. 5.
    CIFUENTES-SILVA E,CABELLO-VERRUGIO C.Bile acids as signaling molecules:Role of ursodeoxycholic acid in cholestatic liver disease[J].Curr Protein Pept Sci,2024,25(3):206-214.
  6. 6.
    SUN X L,HU X,ZHANG Y T.Clinical application of ursodeoxycholic acid[J].Chin J Pharmacovigil,2022,19(10):1149-1153.
  7. 7.
    WANG J,OUYANG B C.Advances in pharmacology and pharmacokinetics of Yinchenhao decoction in prevention and treatment of liver diseases[J].Drug Eval Res,2021,44(3):628-637.
  8. 8.
    CUI F C,ZUO L.Clinical observation of modified Yinchenhao decoction combined with ursodeoxycholic acid in the treatment of cholestasis liver disease with combined syndrome of dampness and blood stasis[J].Henan Tradit Chin Med,2023,43(7):992-996.
  9. 9.
    LUO H B,HE W Z,LI D S,et al.Clinical effect of Jiawei Yinchenhao decoction on nonalcoholic fatty liver disease and its influence on intestinal flora[J].World J Integr Tradit West Med,2021,16(9):1746-1750.
  10. 10.
    ZUO L,CUI F C.Clinical study on supplemented Yinchenhao decoction in the treatment of cirrhosis with syndrome of dampness-heat internal accumulation[J].Henan Tradit Chin Med,2023,43(3):350-353.
  11. 11.
    YOKODA R T,RODRIGUEZ E A.Review:Pathogenesis of cholestatic liver diseases[J].World J Hepatol,2020,12(8):423-435.
  12. 12.
    FUCHS C D,TRAUNER M.Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology[J].Nat Rev Gastroenterol Hepatol,2022,19(7):432-450.
  13. 13.
    GHANBARINEJAD V,OMMATI M M,JIA Z P,et al.Disturbed mitochondrial redox state and tissue energy charge in cholestasis[J].J Biochem Mol Toxicol,2021,35(9):e22846.
  14. 14.
    CHEN J,ZHANG S J.The role of inflammation in cholestatic liver injury[J].J Inflamm Res,2023,16:4527-4540.
  15. 15.
    YU L L,LIU Y R,WANG S H,et al.Cholestasis:Exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies[J].Gut Microbes,2023,15(1):2181930.
  16. 16.
    HUANG LP,XU Y H,DENG M Z,et al.Research progress on chemical constituents,pharmacological mechanism and clinical application of Artemisiae Scopariae Herba[J].Nat Prod Res Dev,2021,33(4):676-690.
  17. 17.
    CHEN R,HE Z X,YAN Y,et al.Research progress on pharmacological and toxic effects of Gardeniae Fructus and its main components[J].Chin Tradit Herbal Drugs,2023,54(18):6092-6105.
  18. 18.
    ZHANG K X,YAO Q Y,WU F M,et al.Research progress on chemical constituents and pharmacological effects of medicinal plants in genus Rheum[J].Chin J New Drugs,2022,31(6):555-566.
  19. 19.
    FU Z W,LI Z X,HU P,et al.A practical method for the rapid detection and structural characterization of major constituents from traditional Chinese medical formulas:Analysis of multiple constituents in Yinchenhao Tang[J].Anal Methods,2015,7(11):4678-4690.
  20. 20.
    QIN C P,QIU Q,LI P F,et al.Research progress of classical prescription Yinchenhao decoction in treating hepatobiliary diseases and predictive analysis of quality markers[J].Chin Arch Tradit Chin Med,2024,42(4):208-214.
  21. 21.
    LING Q H,ZHENG Y Q,CHEN J J,et al.Clinical efficacy of modified Yinchenhao decoction combined with ursodeoxycholic acid in the treatment of primary biliary cholangitis and effect on FGF19[J].Shanghai J Tradit Chin Med,2020,54(S1):41-43.
  22. 22.
    WU L F,WANG Z M,HE K Q,et al.Chemical constituents and pharmacological effects of Paeoniae Radix Rubra:A review[J].Chin J Exp Tradit Med Form,2021,27(18):198-206.
  23. 23.
    ZHANG S R,ZHAO H S,TONG M R,et al.Chemical constituents,pharmacological effects of Moutan Cortex and predictive analysis on its quality marker(Q-Marker)[J].Chin Tradit Herbal Drugs,2022,53(16):5215-5224.
  24. 24.
    CHEN J P,ZHANG K X,LIU Y,et al.Research progress on chemical constituents and pharmacological actions of Rehmannia glutinosa[J].Chin Tradit Herbal Drugs,2021,52(6):1772-1784.
  25. 25.
    LI K D,CAO Z J,AO H.Research progress on chemical components and pharmacological effects of atractylodes[J].J Chengdu Univ Tradit Chin Med,2024,47(6):73-80.
  26. 26.
    LIU D W,HE L L,CUI N,et al.Research progress of chemical constituents,pharmacological action and quality marker prediction of Largehead Atractylodes Rhizome[J].Inf Tradit Chin Med,2024,41(1):65-78.
  27. 27.
    GUAN X T,YANG H N,ZHANG J C,et al.Research progress on chemical constituents and pharmacological effects of chenpi (dried tangerine peel)[J].Chin Arch Tradit Chin Med,2024,42(6):41-49,266.
  28. 28.
    LI W H,LI X J,ZHANG T,et al.Effect of Huoxue Qingjie Ling on bile acid metabolism of cholestatic liver disease rats[J].Shandong Med J,2020,60(19):21-24.
  29. 29.
    FENG K R,LI W X,WANG X Y,et al.Chemical components and pharmacological action for Salviae Miltiorrhizae Radix et Rhizoma and predictive analysis on quality markers[J].Chin Tradit Herbal Drugs,2022,53(2):609-618.
  30. 30.
    YUAN R Y K,WANG Q Q,HE J,et al.Research progress on pharmacological effects and mechanism of Pulsatilla chinensis[J].Drug Eval Res,2024,47(7):1421-1432.
  31. 31.
    CHEN S L,HAN L.Modern research progress on Patriniae[J].J Guangdong Pharm Univ,2017,33(6):816-821.
  32. 32.
    XIE R Q,WANG C F.Research progress on chemical constituents and pharmacological effects of prepared glycyrrhiza[J].Inf Tradit Chin Med,2023,40(4):84-89.
  33. 33.
    VITALE G,MATTIACCIO A,CONTI A,et al.Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis[J].Int J Mol Sci,2023,24(6):5823.
  34. 34.
    WANG X,XIONG W Q,WANG X,et al.Ursolic acid attenuates cholestasis through NRF2-mediated regulation of UGT2B7 and BSEP/MRP2[J].Naunyn Schmiedebergs Arch Pharmacol,2024,397(4):2257-2267.
  35. 35.
    CHANG J H,PLISE E,CHEONG J,et al.Evaluating the in vitro inhibition of UGT1A1,OATP1B1,OATP1B3,MRP2,and BSEP in predicting drug-induced hyperbilirubinemia[J].Mol Pharm,2013,10(8):3067-3075.
  36. 36.
    PAN Q,ZHU G Y,XU Z Q,et al.Organic anion transporting polypeptide (OATP) 1B3 is a significant transporter for hepatic uptake of conjugated bile acids in humans[J].Cell Mol Gastroenterol Hepatol,2023,16(2):223-242.
  37. 37.
    DENK G U,SOROKA C J,MENNONE A,et al.Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis[J].Hepatology,2004,39(5):1382-1389.
  38. 38.
    YI Y X,DING Y,ZHANG Y,et al.Yinchenhao decoction ameliorates alpha-naphthylisothiocyanate induced intrahepatic cholestasis in rats by regulating phase Ⅱ metabolic enzymes and transporters[J].Front Pharmacol,2018,9:510.
  39. 39.
    KATAFUCHI T,MAKISHIMA M.Molecular basis of bile acid-FXR-FGF15/19 signaling axis[J].Int J Mol Sci,2022,23(11):6046.
  40. 40.
    XU Y,CHEN Y,XU Y Y,et al.Study on mechanism of modified Yinchenhao decoction on liver injury induced by α-naphthyl isothiocyanate in mice with cholestasis[J].Acad J Shanghai Univ Tradit Chin Med,2023,37(6):41-48.
  41. 41.
    KOH H,PARK G S,SHIN S M,et al.Mitochondrial mutations in cholestatic liver disease with biliary atresia[J].Sci Rep,2018,8(1):905.
  42. 42.
    LIU J J,LI Z L,SHANG H T.Study on Yinchenhao decoction regulating bile acid metabolism and intervening the mitochondrial DNA damage in liver cells of rats with obstructive jaundice[J].Tianjin Med J,2020,48(9):839-842.
  43. 43.
    KHAYAT M T,MOHAMMAD K A,MOHAMED G A,et al.γ-Mangostin abrogates AINT-induced cholestatic liver injury:Impact on Nrf2/NF-κB/NLRP3/Caspase-1/IL-1β/GSDMD signalling[J].Life Sci,2023,322:121663.
  44. 44.
    SHI Y,SU W T,ZHANG L,et al.TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation[J].Front Immunol,2021,11:609060.
  45. 45.
    LI W H,ZHANG G X,NIE W,et al.Therapeutic effect of modified Yinchenhao decoction on cholestatic liver disease in rats[J].Chin J Exp Tradit Med Form,2020,26(4):29-34.
  46. 46.
    YANG R K,ZHU S T,PISCHKE S E,et al.Bile and circulating HMGB1 contributes to systemic inflammation in obstructive jaundice[J].J Surg Res,2018,228:14-19.
  47. 47.
    MA W T,CHEN D K.Immunological abnormalities in patients with primary biliary cholangitis[J].Clin Sci,2019,133(6):741-760.
  48. 48.
    HE S M,FU J,WANG Z,et al.Analysis of the regulatory effect of Yinchenhao decoction on IL-6 and immune function after operation on obstructive jaundice with liver-gallbladder damp-heat syndrome[J].China Mod Doct,2022,60(14):143-145,149.
  49. 49.
    BELLEZZA I,GIAMBANCO I,MINELLI A,et al.Nrf2-Keap1 signaling in oxidative and reductive stress[J].Biochim Biophys Acta Mol Cell Res,2018,1865(5):721-733.
  50. 50.
    LI C L,LIU M G,DENG L,et al.Oxyberberine ameliorates TNBS-induced colitis in rats through suppressing inflammation and oxidative stress via Keap1/Nrf2/NF-κB signaling pathways[J].Phytomedicine,2023,116:154899.
  51. 51.
    LIU J J,CHEN S,YUAN H X,et al.Effect of Yinchenhao decoction on renal oxidative stress injury in rats with obstructive jaundice and its mechanism of action based on the nuclear factor erythroid 2-related factor 2 signaling pathway[J].J Clin Hepatol,2023,39(5):1126-1133.
  52. 52.
    YUAN S.Mechanism of Yinchenhao decoction regulating Keap1 / Nrf2 pathway to prevent liver injury in rats with dampness heat syndrome of cholestatic liver disease[D].Jinan:Shandong University of Traditional Chinese Medicine,2022.
  53. 53.
    CUNNINGHAM R P,MOORE M P,DASHEK R J,et al.Critical role for hepatocyte-specific ENOS in NAFLD and NASH[J].Diabetes,2021,70(11):2476-2491.
  54. 54.
    ANAVI S,TIROSH O.iNOS as a metabolic enzyme under stress conditions[J].Free Radic Biol Med,2020,146:16-35.
  55. 55.
    CHEN S,LIU J J,SHANG H T,et al.Based on network pharmacology,molecular docking,and experiments to explore the mechanism of Yinchenhao decoction in regulating oxidative stress of obstructive jaundice[J].J Tianjin Med Univ,2021,27(6):595-602.
  56. 56.
    IURLARO R,MUÑOZ-PINEDO C.Cell death induced by endoplasmic reticulum stress[J].FEBS J,2016,283(14):2640-2652.
  57. 57.
    LI M S,ZHANG G X,WEI Y Y,et al.Experimental study on effects of Yinchenhao decoction on endoplasmic reticulum stress PERK pathway in cholestasis liver fibrosis rats[J].Chin J Tradit Med Sci Technol,2016,23(5):535-538.
  58. 58.
    CHENG C S,DONG W G.Aloe-emodin induces endoplasmic reticulum stress-dependent apoptosis in colorectal cancer cells[J].Med Sci Monit,2018,24:6331-6339.
  59. 59.
    LI M S,ZHANG G X,WEI Y Y,et al.Effects of Yinchenhao decoction on endoplasmic reticulum stress pathway of caspase-12 in hepatic fibrosis rats[J].World Chin Med,2016,11(9):1839-1841.
  60. 60.
    XU H B,SHEN X M,LI X K,et al.The natural product dehydrocurvularin induces apoptosis of gastric cancer cells by activating PARP-1 and caspase-3[J].Apoptosis,2023,28(3/4):525-538.
  61. 61.
    YU W J,ZHU H L,HUANG R X,et al.Roles of Cyt-C/Caspase-9/Caspase-3/Bax/Bcl-2 pathway in Cd-induced testicular injury in rats and the protective effect of quercetin[J].Toxicon,2024,237:107561.
  62. 62.
    WANG Y W,GUO Z,DU Z,et al.Comparative study of Yinchenhao decoction and Huangqi decoction by regulating apoptosis via the mitochondrial pathway in treatment and prevention of chronic cholestatic liver injury[J].China J Tradit Chin Med Pharm,2023,38(1):155-160.
  63. 63.
    ISHTEYAQUE S,YADAV K S,VERMA S,et al.CYP2E1 triggered GRP78/ATF6/CHOP signaling axis inhibit apoptosis and promotes progression of hepatocellular carcinoma[J].Arch Biochem Biophys,2023,745:109701.
  64. 64.
    XIANG C C,HAN F,SHI Y X.Research on activating transcription factor 6 pathway and its related factors' regulation on unfolded protein reaction in endoplasmic reticulum stress[J].Acta Anat Sin,2015,46(6):857-861.
  65. 65.
    SUN Y M,LIU H,LIU J J,et al.Influence of Yinchenhao decoction on the expression of ATF6/GRP78/CHOP apoptotic signaling pathway in hepatocyte of rats with obstructive jaundice[J].J Tianjin Med Univ,2023,29(3):252-257.
  66. 66.
    DUAN Y T,HUANG J J,SUN M J,et al.Poria cocos polysaccharide improves intestinal barrier function and maintains intestinal homeostasis in mice[J].Int J Biol Macromol,2023,249:125953.
  67. 67.
    HUANG L,LU T,ZHANG Y L,et al.Correlation between abnormal serum detection indicators of intestinal barrier function with metabolic diseases[J].Chongqing Med J,2024,53(24):3789-3792.
  68. 68.
    HAN B,LV X D,LIU G F,et al.Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-α4β7-integrin therapy in humanized mice with colitis[J].Gut Microbes,2023,15(1):2232143.
  69. 69.
    ZHAO J L.Chinese herbs for clearing heat and removing dampness on expression of gpbar1 and FXR in intestinal mucosa of rats with obstructive jaundice[D].Dalian:Dalian Medical University,2019.
  70. 70.
    GONG H X,DONG H C,SU Y,et al.Effect of Dabupi decoction combined with oxaliplatin on intestinal barrier injury in tumor-bearing mice with gastric cancer based on TLR4/MyD88/NF-κB signaling pathway[J].Pharmacol Clin Chin Mater Med,2023,39(8):31-36.
  71. 71.
    LI J T,JIAO J Z,WEI H L,et al.Effect of Yinchenhao decoction on intestinal mucosal barrier and NF-κB in rats with acute intrahepatic cholestasis[J].Shaanxi J Tradit Chin Med,2019,40(5):547-549.
  72. 72.
    HOU X D,ZHU L,ZHANG G Q,et al.The therapeutic effect and the underlying mechanism of Yinchenhao decoction and its different modified combinations on estrogen induced cholestasis rats[J].Chin J Hosp Pharm,2017,37(15):1454-1458.
  73. 73.
    WU H B,SHE S F,LAN S Y.Mechanism of Yinzhihuang injection for intrahepatic cholestasis based on FXR[J]. Liaoning J Tradit Chin Med,2016,43(4):845-848.
  74. 74.
    MIAO Y H,SUN R F.Effect of Yinchenhao decoction on Th1/Th2 balance in patients with intrahepatic cholestasis of pregnancy[J].Chin J Integr Tradit West Med,2014,34(8):1017-1018.
  75. 75.
    FU H H.Value analysis of Yinchenhao decoction in the treatment of intrahepatic cholestasis of pregnancy[J].Pract Clin J Integr Tradit Chin West Med,2017,17(10):45-47.
  76. 76.
    YANG X B.Effect of Yinchenhao decoction on Th1/Th2 balance in patients with intrahepatic cholestasis of pregnancy[J].Mod J Integr Tradit Chin West Med,2019,28(17):1885-1887,1891.
  77. 77.
    CHEN W Z,XIONG Z H,HONG Q H,et al.Clinical efficacy of Jiawei Yinchenhao decoction combined with S-adenosylmethionine and its effects on serum TBA,IL-17 and TGF-β levels in patients with intrahepatic cholestasis of pregnancy[J].Zhejiang Med J,2020,42(22):2439-2442.
  78. 78.
    WANG S P,LI Y F,SUN X,et al.Efficacy of Yinchenhao decoction combined with ursodeoxycholic acid in the treatment of ICP and the effect of Th17/Treg imbalance on pregnancy outcome[J].Shaanxi J Tradit Chin Med,2023,44(8):1074-1077.
  79. 79.
    ZHU Z W,ZHU P S,MIAO M S.Evaluation of cholestatic liver disease animal model based on clinical syndrome characteristics of integrated traditional Chinese and Western medicine[J].J Clin Hepatol,2023,39(12):2959-2964.
  80. 80.
    WANG L L,ZHU Z W,ZHAO J H,et al.Mechanism of Yinchenhao Tang regulating pyroptosis to interfere with cholestatic liver injury[J].Chin J Exp Tradit Chin Med Form,2025,doi:.
  81. 81.
    ZHAO J H,ZHU Z W,WANG L L,et al.Investigation into mechanism of Yinchenhao decoction in modulating macrophage activation to combat cholestatic liver injury[J].Chin J Exp Tradit Chin Med Form,2025,doi:.
  82. 82.
    ZHU Z W,WANG L L,ZHAO J H,et al.Mechanism of Yinchenhao Tang regulating Fas/Caspase-8/Caspase-3 signaling pathway to improve cholestatic liver injury[J].Chin J Exp Tradit Chin Med Form,2025,doi:.
  83. 83.
    ZHU Z W,YANG Y,ZHAO J H,et al.Mechanism of Yinchenhao Tang in improving cholestatic liver injury by inhibiting TLR4/MyD88/NF-κB pathway through FXR[J].Chin J Exp Tradit Chin Med Form,2025,doi:.

Читать полностью

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website